Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 397

1.

Clonal Relationship Between Lichen Sclerosus, Differentiated Vulvar Intra-epithelial Neoplasia and Non HPV-related Vulvar Squamous Cell Carcinoma.

Pouwer AW, VAN DEN Einden LCG, VAN DER Linden M, Hehir-Kwa JY, Yu J, Hendriks KM, Kamping EJ, Eijkelenboom A, Massuger LFAG, Bulten J, VAN Tilborg AAG, DE Hullu JA, Kuiper RP.

Cancer Genomics Proteomics. 2020 Mar-Apr;17(2):151-160. doi: 10.21873/cgp.20175.

2.

Collaboration Benefits All.

Hemida RA, van Doorn HC, Massuger LFAG.

JCO Glob Oncol. 2020 Feb;6:56-58. doi: 10.1200/JGO.19.00237. No abstract available.

3.

The risk of cervical cancer after cervical intraepithelial neoplasia grade 3: A population-based cohort study with 80,442 women.

Loopik DL, IntHout J, Ebisch RMF, Melchers WJG, Massuger LFAG, Siebers AG, Bekkers RLM.

Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30067-6. doi: 10.1016/j.ygyno.2020.01.023. [Epub ahead of print]

4.

Short-term surgical complications after radical hysterectomy-A nationwide cohort study.

Wenzel HHB, Kruitwagen RFPM, Nijman HW, Bekkers RLM, van Gorp T, de Kroon CD, van Lonkhuijzen LRCW, Massuger LFAG, Smolders RGV, van Trommel NE, Yigit R, Zweemer RP, van der Aa MA.

Acta Obstet Gynecol Scand. 2020 Jan 18. doi: 10.1111/aogs.13812. [Epub ahead of print]

PMID:
31955408
5.

The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population-based study.

Loopik DL, Ebisch RM, IntHout J, Melchers WJ, Massuger LF, Bekkers RL, Siebers AG.

Int J Cancer. 2019 Dec 17. doi: 10.1002/ijc.32834. [Epub ahead of print]

PMID:
31846057
6.

Oral contraceptive and intrauterine device use and the risk of cervical intraepithelial neoplasia grade III or worse: a population-based study.

Loopik DL, IntHout J, Melchers WJG, Massuger LFAG, Bekkers RLM, Siebers AG.

Eur J Cancer. 2020 Jan;124:102-109. doi: 10.1016/j.ejca.2019.10.009. Epub 2019 Nov 21.

7.

Risk prediction of cervical abnormalities: The value of sociodemographic and lifestyle factors in addition to HPV status.

van der Waal D, Bekkers RLM, Dick S, Lenselink CH, Massuger LFAG, Melchers WJG, Schmeink CE, Siebers AG, Broeders MJM.

Prev Med. 2020 Jan;130:105927. doi: 10.1016/j.ypmed.2019.105927. Epub 2019 Nov 19.

8.

Two types of primary mucinous ovarian tumors can be distinguished based on their origin.

Simons M, Simmer F, Bulten J, Ligtenberg MJ, Hollema H, van Vliet S, de Voer RM, Kamping EJ, van Essen DF, Ylstra B, Schwartz LE, Wang Y, Massuger LF, Nagtegaal ID, Kurman RJ.

Mod Pathol. 2019 Nov 6. doi: 10.1038/s41379-019-0401-y. [Epub ahead of print]

PMID:
31695154
9.

Clinical practice variation and overtreatment risk in women with abnormal cervical cytology in the Netherlands; two-step versus see-and-treat approach.

Loopik DL, Siebers AG, Melchers WJG, Massuger LFAG, Bekkers RLM.

Am J Obstet Gynecol. 2019 Oct 21. pii: S0002-9378(19)31221-9. doi: 10.1016/j.ajog.2019.10.004. [Epub ahead of print]

10.

RNA-based high-risk HPV genotyping and identification of high-risk HPV transcriptional activity in cervical tissues.

van den Heuvel CNAM, Loopik DL, Ebisch RMF, Elmelik D, Andralojc KM, Huynen M, Bulten J, Bekkers RLM, Massuger LFAG, Melchers WJG, Siebers AG, Leenders WPJ.

Mod Pathol. 2019 Sep 19. doi: 10.1038/s41379-019-0369-7. [Epub ahead of print]

PMID:
31537894
11.

Mutational analysis of cervical cytology improves diagnosis of endometrial cancer: A prospective multicentre cohort study.

Reijnen C, van der Putten LJM, Bulten J, Snijders MPLM, Küsters-Vandevelde HVN, Sweegers S, Vos MC, van der Wurff AAM, Ligtenberg MJL, Massuger LFAG, Eijkelenboom A, Pijnenborg JMA.

Int J Cancer. 2020 May 1;146(9):2628-2635. doi: 10.1002/ijc.32686. Epub 2019 Nov 22.

PMID:
31523803
12.

Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study.

Reijnen C, Visser NC, Kasius JC, Boll D, Geomini PM, Ngo H, Van Hamont D, Pijlman BM, Vos MC, Bulten J, Snijders MP, Massuger LF, Pijnenborg JM.

J Gynecol Oncol. 2019 Sep;30(5):e70. doi: 10.3802/jgo.2019.30.e70.

13.

Polymorphisms in MMP-14 and MMP-2 genes and ovarian cancer survival.

Vos MC, van Tilborg A, Brands WJ, Boll D, van Hamont D, van der Putten H, Pijlman B, van der Wurff AAM, van Kuppevelt TH, Massuger LFAG.

Cancer Biomark. 2019;25(3):233-241. doi: 10.3233/CBM-181826.

PMID:
31282404
14.

Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.

Koole SN, van Lieshout C, van Driel WJ, van Schagen E, Sikorska K, Kieffer JM, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AG, Verwaal VJ, Van de Vijver KK, Aaronson NK, van Tinteren H, Sonke GS, van Harten WH, Retèl VP.

J Clin Oncol. 2019 Aug 10;37(23):2041-2050. doi: 10.1200/JCO.19.00594. Epub 2019 Jun 28.

PMID:
31251694
15.

Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis.

Reijnen C, IntHout J, Massuger LFAG, Strobbe F, Küsters-Vandevelde HVN, Haldorsen IS, Snijders MPLM, Pijnenborg JMA.

Oncologist. 2019 Sep;24(9):e880-e890. doi: 10.1634/theoncologist.2019-0117. Epub 2019 Jun 11.

16.

Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: a retrospective study.

van Weelden WJ, Fasmer KE, Tangen IL, IntHout J, Abbink K, van Herwaarden AE, Krakstad C, Massuger LFAG, Haldorsen IS, Pijnenborg JMA.

BMC Cancer. 2019 Jun 7;19(1):547. doi: 10.1186/s12885-019-5770-6.

17.

Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review.

van Weelden WJ, Massuger LFAG; ENITEC, Pijnenborg JMA, Romano A.

Front Oncol. 2019 May 7;9:359. doi: 10.3389/fonc.2019.00359. eCollection 2019.

18.

Peptide-mediated delivery of therapeutic mRNA in ovarian cancer.

van den Brand D, Gorris MAJ, van Asbeck AH, Palmen E, Ebisch I, Dolstra H, Hällbrink M, Massuger LFAG, Brock R.

Eur J Pharm Biopharm. 2019 Aug;141:180-190. doi: 10.1016/j.ejpb.2019.05.014. Epub 2019 May 16.

PMID:
31103743
19.

Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.

Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, Brucker SY, Kwon JS, McAlpine JN, Pijnenborg JMA.

Gynecol Oncol. 2019 Jul;154(1):124-130. doi: 10.1016/j.ygyno.2019.03.097. Epub 2019 May 15.

PMID:
31103324
20.

Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands.

Polman NJ, de Haan Y, Veldhuijzen NJ, Heideman DAM, de Vet HCW, Meijer CJLM, Massuger LFAG, van Kemenade FJ, Berkhof J.

Prev Med. 2019 Aug;125:5-11. doi: 10.1016/j.ypmed.2019.04.025. Epub 2019 May 2.

PMID:
31054907

Supplemental Content

Loading ...
Support Center